Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

5-Amino-1MQ regulatory status

Current status of 5-Amino-1MQ in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of 5-Amino-1MQ?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
FDA and compounding
Not FDA approved and not an active ingredient in any approved drug. It does not appear in FDA's Category 2 list or on the 503A bulks list as of the pages current to April 2026, and it has no USP monograph, so it does not meet any of the three bulk substance criteria in section 503A. That leaves no federal basis for a compounding pharmacy to compound it despite its widespread marketing as a compounded capsule. It was not part of the July 2026 advisory committee review.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.
  2. Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Full 5-Amino-1MQ page: evidence, dosing in the literature, and sources

How has the status of 5-Amino-1MQ changed over time?

No dated regulatory event has been recorded for 5-Amino-1MQ. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for 5-Amino-1MQ and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  2. [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026

From the blog